By occupying the SAM-binding pocket and inducing conformational changes in DOT1L, EPZ-5676, a derivative of EPZ004777, is another effective DOT1L inhibitor that led to tumor regression in rat xenograft models of MLL-rearranged leukemia (Daigle et al., 2013). Here, DOT1L is linked to neoplasm.